Drug Trial Radar · NCT01039506
An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
Last checked: Nov 19, 2026Latest source record: May 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,376
Actual
Start
Oct 15, 2009
Primary completion
Apr 28, 2016
Study completion Jul 1, 2016
Sponsor
- Lead sponsor
- Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Dec 25, 2009
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.
Conditions
- Metastatic Colorectal Cancer
Interventions
CPT-11 based regimensDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: Within 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Clinical Oncology, National Defense Medical College Hospital
Tokorozawa-shi, Saitama, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.